Opinion
Video
Contemporary Guidelines for CRM Conditions
Key Takeaways
- Professional organizations have developed guidelines to manage the interconnectivity of CRM conditions, reflecting advancements in understanding cardiovascular, renal, and metabolic health.
- Recent updates in guidelines include the integration of novel therapeutic agents and personalized treatment strategies, enhancing evidence-based practices.
Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.
Video content above is prompted by the following:
- How do guidelines from professional organizations, including ACC, AHA, ADA, KDIGO, ACE, and DCRMi, address the management and interconnectivity of CRM conditions?
- How have these guidelines evolved in recent years? What are the notable guideline updates in recent years?
- What impact have these guidelines had on the treatment outcomes of patients with CRM conditions?
- What gaps are there in these guidelines regarding the management of CRM conditions?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
